Rhythm Pharmaceuticals and LG Chem Amend Exclusive License Agreement for Bivamelagon

Shots: Rhythm Pharmaceuticals has amended its global exclusive license agreement with LG Chem for bivamelagon (formerly LB54640), an investigational oral small-molecule MC4R agonist Rhythm will pay 50M in 4 fixed installments through Sep 2029 (0M upfront), while the prior low-to-mid-single-digit royalty is replaced by a 1% royalty on global sales of its MC4R portfolio from Jan 2029 (or bivamelagon’s first sale), plus up to 00M milestone on reaching B in annual MC4R sales Rhythm also secured a 5yr. term-loan facility of up to 50M (00M committed) led by HealthCare Royalty with Blackstone Ref: GlobeNewswire  |   Image: Rhythm Pharmaceuticals | LG Chem  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Rhythm Pharmaceuticals and LG Chem Amend Exclusive License Agreement for Bivamelagon appeared first on PharmaShots.